Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, Zhang XY, Liu JL, Li JL. Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol 2014; 20(4): 1095-1106 [PMID: 24574784 DOI: 10.3748/wjg.v20.i4.1095]
Corresponding Author of This Article
Zheng-Xu Wang, MD, PhD, Associate Professor, Director of Biotherapy Center, the General Hospital of Beijing Military Command, No.5 of Nan Men Cang Rd, Dongcheng District, Beijing 100700, China. zhxwang18@hotmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, Zhang XY, Liu JL, Li JL. Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol 2014; 20(4): 1095-1106 [PMID: 24574784 DOI: 10.3748/wjg.v20.i4.1095]
World J Gastroenterol. Jan 28, 2014; 20(4): 1095-1106 Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1095
Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis
Zheng-Xu Wang, Jun-Xia Cao, Zhi-Ping Liu, Yu-Xin Cui, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li
Zheng-Xu Wang, Jun-Xia Cao, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li, Biotherapy Center, the General Hospital of Beijing Military Command, Beijing 100700, China
Zhi-Ping Liu, Department of Immunology, St Jude Children’s Research Hospital, Memphis, TN 38105, United States
Yu-Xin Cui, School of Cellular and Molecular Medicine, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom
Author contributions: Wang ZX designed the research; Cao JX and Li CY performed the research; Liu ZP and Cui YX contributed new reagents or analytic tools; Cao JX, Li CY, Li D, Zhang XY, Liu JL and Li JL analyzed data; Wang ZX, Cao JX, Liu ZP and Cui YX wrote the paper.
Supported by National Natural Science Foundation of China, No. 31171427 and No. 30971651 to Wang ZX; National Natural Science Foundation of China, No. 30700974 to Cao JX; and Postdoctoral Foundation of China, No. 20060400775 to Cao JX
Correspondence to: Zheng-Xu Wang, MD, PhD, Associate Professor, Director of Biotherapy Center, the General Hospital of Beijing Military Command, No.5 of Nan Men Cang Rd, Dongcheng District, Beijing 100700, China. zhxwang18@hotmail.com
Telephone: +86-10-66721169 Fax: +86-10-64038276
Received: September 10, 2013 Revised: October 28, 2013 Accepted: November 12, 2013 Published online: January 28, 2014 Processing time: 138 Days and 9.1 Hours
Core Tip
Core tip: A growing body of knowledge on tumor immunosurveillance and loss thereof has contributed to the refinement of anti-tumor immunotherapy. The aim of our meta-analysis was to determine whether an association exists between dendritic cell (DC)-cytokine-induced killer (CIK) cell therapy combined with chemotherapy and chemotherapy alone. Our analysis demonstrates that DC-CIK therapy improved 1, 2 and 3-year overall survival, 1, 2 and 3-year disease-free survival, overall response rate and immune indices in colon cancer. In all, the combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses, suggesting the possible application of this promising adjuvant immunotherapy in colon cancer.
